Contents

Dalcetrapib

Dalcetrapib

Names
IUPAC name S-[2-({[1-(2-Ethylbutyl)cyclohexyl]carbonyl}amino)phenyl]-2-methylpropanethioate
Identifiers
CAS Number	211513-37-0
3D model (JSmol)	Interactive image Interactive image
ChEMBL	ChEMBL313006
ChemSpider	5293737
ECHA InfoCard	100.250.741
KEGG	D09708
PubChem CID	6918540
UNII	3D050LIQ3H Y
CompTox Dashboard (EPA)	DTXSID70943475
InChI InChI=1S/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26) Key: YZQLWPMZQVHJED-UHFFFAOYSA-N InChI=1/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26) Key: YZQLWPMZQVHJED-UHFFFAOYAR
SMILES O=C(Sc1ccccc1NC(=O)C2(CC(CC)CC)CCCCC2)C(C)C CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C
Properties
Chemical formula	C23H35NO2S
Molar mass	389.5945
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Chemical compound

Dalcetrapib (INN,^[1] codenamed JTT-705) is a CETP inhibitor which was being developed by Hoffmann–La Roche until May 2012.^[2][3] The drug was aimed at raising the blood levels of HDL cholesterol.^[4] Prevailing observations indicate that high HDL levels correlate with better overall cardiovascular health, though it remains unclear whether raising HDL levels consequently leads to an increase in cardiovascular health.^[5]

A 24-week clinical trial showed that dalcetrapib did increase HDL-C levels, supporting the agent's desired effect.^[6] Further, the dal-PLAQUE phase IIb trial found evidence of plaque reduction.^[7] Plaque reduction is an anticipated observation following an increase in HDL.^{[citation needed]}

As of 2010^[update] five phase II trials had started and there was no evidence of the raised blood pressure seen with torcetrapib.^[6]

dal-VESSEL phase IIb trial found no evidence of flow-mediated dilatation improvement. A 17% increase of Lp-PLA₂ mass level was noted.^[8] Lp-PLA₂ is associated with coronary heart disease and stroke.^{[citation needed]}

dal-OUTCOMES phase III trial passed its first interim review in July, 2011,^[9] however, development was halted on May 7, 2012 “due to a lack of clinically meaningful efficacy.”.^[3]

The results of dal-OUTCOMES III were published in November, 2012.^[10]

A pharmacogenomic genome-wide association study (GWAS) reported that patients from the dal-OUTCOMES study bearing a protective allele at SNP rs1967309 in the ADCY9 gene may have benefited from dalcetrapib therapy.^[11] Changes in inflammation and cholesterol efflux capacity may in part explain the benefits associated with the protective genotype.^[12] The Dal-GenE trial was performed to validate these observations. This clinical trial is a randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular risk in patients with recent acute coronary syndrome bearing the protective genotype.^[13] The results published in 2022 showed that Dalcetrapib did not significantly reduce the risk of occurrence of the primary endpoint of ischaemic cardiovascular events at end of study in patients with an acute coronary syndrome within 1-3 months and the AA genotype at variant rs1967309 in the ADCY9 gene.^[14]

See also[edit]

• CETP inhibitor

References[edit]